PÉKIN, 3 juin 2023 /PRNewswire/ — La ville de Sanmenxia, dans la province du Henan, en Chine centrale, a mis en œuvre 78 projets pour un investissement total de 92,76 milliards de yuans (environ 13,07 milliards de dollars américains) lors du 28e festival de tourisme culturel du fleuve…
Month: June 2023
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent CHICAGO, June 3, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson…
NEW YORK, June 3, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Bowlero Corp. (NYSE: BOWL) resulting from allegations that Bowlero may have issued materially misleading…
SAN DIEGO, June 3, 2023 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Luminar Technologies, Inc. (NASDAQ: LAZR) securities between February 28, 2023 and March 17, 2023, both dates inclusive (the “Class Period”) have until July…
SAN DIEGO, June 3, 2023 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Funko, Inc. (NASDAQ: FNKO) common stock on a U.S. open market between May 6, 2022 and March 1, 2023, inclusive (the “Class Period”) have until August 1, 2023…
NEW YORK, June 3, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Microvast Holdings, Inc. (NASDAQ: MVST, MVSTW) resulting from allegations that Microvast may have issued…
CHICAGO, June 3, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class…
Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will…
Une présentation orale intitulée « Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results » sera présentée par Howard Safran, directeur médical, lors de la session ASCO…
NINGBO, China, June 3, 2023 /PRNewswire/ — A report from Ningbo Media Group: A new beginning awaits! On June 3, the 2023 Hangzhou Bay National Wetland Park Birdwatching Festival began at the wetland park in Ningbo, the city’s only locale designated as a prime bird watching site in…